Sarepta's DMD gene therapy inches closer to market as FDA declines to hold advisory meeting

The FDA won’t be holding an advisory panel meeting for Sarepta Therapeutics’ SRP-9001, which is now that much closer to becoming the first gene therapy for Duchenne muscular dystrophy (DMD).